Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer

National Medical Journal of China

Volumn 89, Issue 22, 2009, Pages 1544-1548

  Zhang, Yi Fei ^a   Yu, Yong Feng ^a   Lu, Shun ^a  

^a SHANGHAI CHEST HOSPITAL   (China)

Author keywords

Antineoplastic agents; Antineoplastic protocols; Carcinoma, non small cell lung; Docetaxel; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PLATINUM; TAXOID;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84871270273     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.22.012     Document Type: Article

References (13)

1. Boukovinas I, Kosmidis P. Treatment of non-small cell lung cancer patients with performance status2 (PS2). Lung Cancer, 2009, 63: 10-15.
2. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist, 2008, 13: 28-36.
3. Noble J, Ellis PM, Mackay JA, et al. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol, 2006, 1: 1042-1058.
4. Horn L, Visval A, Leighl NB. Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging, 2007, 24: 411-428.
5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18: 2095-2103.
6. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol, 2000, 18: 2354-2362.
7. Kim YH, Kim JS, Choi YH, et al. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer. Int J Clin Oncol, 2002, 7: 114-119.
8. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol, 2005, 23: 2926-2936.
9. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol, 2003, 21: 3016-3024.
10. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist, 2005, 10: 1-10.
11. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol, 2008, 26: 4244-4252.
12. Eisenhauer E. Docetaxel: current status and future prospects. J Clin Oncol, 1995, 13: 2865-2868.
13. Charoentum C, Thongprasert S, Chewasakulyong B, et al. Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer. J Med Assoc Thai, 2007, 90: 2506-2512.